UroGen Pharma Ltd. (URGN) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, UroGen Pharma reported revenue of $109.8M, up 21.4% from $90.4M the year before. Net income was -$153.5M (a -139.8% net margin). Gross margin was 88.7% and operating margin was -113.7%. Operating activities generated -$162.4M of cash, leaving -$162.7M of free cash flow. At fiscal year end, UroGen Pharma held $200.5M in total assets against $305.9M in total liabilities, including $110.7M of cash and equivalents.
Open the full interactive UroGen Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
UroGen Pharma Key Stats
| Share Price | $38.26 |
|---|---|
| Market Cap | $1.93B |
| Revenue YoY Growth | +21.4% |
| 52-Week Range | $16.65 – $50.29 |
| Shares Outstanding | 50.4 million (basic, 2026 Q2) |
UroGen Pharma Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $11.8M | $48.0M | $64.4M | $82.7M | $90.4M | $109.8M |
| Gross Profit | $10.8M | $42.9M | $56.7M | $73.4M | $81.5M | $97.3M |
| Operating Income | -$126.7M | -$92.3M | -$79.0M | -$65.5M | -$96.8M | -$124.9M |
| Pre-Tax Income | -$125.1M | -$109.4M | -$108.0M | -$98.3M | -$124.0M | -$153.4M |
| Income Tax | $3.4M | $1.4M | $1.8M | $3.9M | $2.8M | $78,000 |
| Net Income | -$128.5M | -$110.8M | -$109.8M | -$102.2M | -$126.9M | -$153.5M |
| Diluted EPS | -$5.90 | -$4.96 | — | — | — | — |
UroGen Pharma Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $27.5M | $37.8M | $51.0M | $72.5M |
| Net Income | -$33.3M | -$26.4M | -$23.6M | -$14.4M |
UroGen Pharma Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $52.9M | $44.4M | $55.4M | $95.0M | $172.0M | $110.7M |
| Current Assets | $115.6M | $114.4M | $128.9M | $169.2M | $276.1M | $186.0M |
| Total Assets | $122.0M | $119.7M | $135.6M | $178.3M | $285.7M | $200.5M |
| Current Liabilities | $21.4M | $22.4M | $23.9M | $31.2M | $45.9M | $46.4M |
| Total Long-Term Debt | — | — | $97.5M | $98.6M | $121.7M | $125.0M |
| Total Liabilities | $25.6M | $111.3M | $225.0M | $243.5M | $294.5M | $305.9M |
| Shareholders' Equity | $96.4M | $8.4M | -$89.4M | -$65.2M | -$8.8M | -$105.5M |
UroGen Pharma Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$105.9M | -$84.9M | -$87.6M | -$76.4M | -$96.8M | -$162.4M |
| Cash From Investing | $93.2M | $4.1M | $1.1M | -$953,000 | -$20.6M | $61.6M |
| Cash From Financing | $16.5M | $72.3M | $97.1M | $116.9M | $194.6M | $39.9M |
| Free Cash Flow | -$107.1M | -$85.6M | -$87.8M | -$76.6M | -$97.1M | -$162.7M |
Figures from UroGen Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full UroGen Pharma financials page for every line item.
UroGen Pharma Company Profile
| Ticker | URGN |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Ra'Anana, Israel |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001668243 |
Frequently Asked Questions
What was UroGen Pharma's revenue in fiscal 2025?
UroGen Pharma (URGN) reported revenue of $109.8M for fiscal 2025.
What is UroGen Pharma's annual revenue history?
UroGen Pharma's annual revenue by fiscal year: 2020: $11.8M; 2021: $48.0M; 2022: $64.4M; 2023: $82.7M; 2024: $90.4M; 2025: $109.8M.
What was UroGen Pharma's net income in fiscal 2025?
UroGen Pharma reported net income of -$153.5M for fiscal 2025.
How much free cash flow did UroGen Pharma generate in fiscal 2025?
UroGen Pharma generated -$162.7M of free cash flow in fiscal 2025.
What was UroGen Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), UroGen Pharma reported revenue of $72.5M.
How much debt does UroGen Pharma have?
UroGen Pharma reported $125.0M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of UroGen Pharma are outstanding?
UroGen Pharma reported a weighted average of 50.4 million basic shares outstanding in 2026 Q2.
What is UroGen Pharma's market cap?
Based on its latest closing price, UroGen Pharma (URGN) has a market capitalization of about $1.93B.
When does UroGen Pharma's fiscal year end?
UroGen Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is UroGen Pharma headquartered?
UroGen Pharma lists its business address in Ra'Anana, Israel in its SEC filings.